drugset / Trial / NCT07177677
A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder
Phase 1
Not yet recruiting
42 enrolled
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Capital Medical University · collab
NaSequentialOpen-labelTreatment
Summary
This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).
Timeline
- Start
- 2025-09-30
- Primary completion
- 2026-12-30
- Completion
- 2028-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donor-derived Mesenchymal Stromal Cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Donor-derived Mesenchymal Stromal Cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Donor-derived Mesenchymal Stromal Cells | Cell therapy | 2e+06 cells/kg | Intravenous |